News FDA approves UCB’s Cimzia in plaque psoriasis The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis
News Andexxa reaches the end of the line in the US AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
